Innoviva, Inc Stock News

MARINA DEL REY, Calif., March 17, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriopha

The Dow slipped 0.1%, the S&P 500 rose 0.1%, and the Nasdaq climbed 0.6%. In the meantime, Q.ai's Artificial Intelligence has brought out today's top buys.

Innoviva (INVA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

I don't think this is a "buy and forget" stock by any stretch of the imagination, but if you get the timing right, it'll be a very profitable trade.

Shares of Innoviva (NASDAQ:INVA) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 14.29% over the past year to $0.48, which beat

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

Top Ranked Value Stocks to Buy for January 5th

Top Ranked Value Stocks to Buy for January 4th

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Top Ranked Value Stocks to Buy for December 29th

Top Ranked Value Stocks to Buy for December 28th

To combat market volatility, create a portfolio of low-beta stocks.

Top Ranked Value Stocks to Buy for December 24th

We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near $12 currently and it is, in fact, down 17% from i

This FTSE 100 stock soared after March's crash, but today dived to its 2020 low. I say this is crazy, because these cheap shares pay a juicy passive income!